BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics has successfully completed a $5.0 million registered direct offering, selling shares and warrants to healthcare-focused institutional investors, including an existing shareholder and a director of the company. The biotech firm plans to allocate the net proceeds towards working capital, research and development, and other corporate activities, aiming to bolster their phase 3 breast cancer studies. The company’s CEO expressed gratitude for the continued support from key investors, reinforcing confidence in BriaCell’s innovative cancer treatment technologies.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
